OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the…
Browsing: brain cancer
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.